Caliper's Q3 Revenues Drop 7 Percent on Lower License, Contract Revenue | GenomeWeb
NEW YORK (GenomeWeb News) – Caliper Life Sciences reported after the close of the market on Monday that its third-quarter revenues fell 7 percent as its license fees and contract revenues took an expected sharp downturn year over year.
 
Caliper also said that it completed the sale of two non-core businesses for close to $21 million.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.